Imagion Biosystems Limited (ASX: IBX) (Imagion or the Company) is pleased to announce a pro-rata non- renounceable rights issue (Offer) to shareholders, on the basis of 1 new share for every 2 Imagion shares held as at 7.00pm (Melbourne time) Friday 28 September 2018 (Record Date).
View the Pro-Rata Non-Renounceable Rights Issue announcement.
Imagion Biosystems’ IND Application for MagSense® Phase 2 Clinical Trial Clears FDA Review
June 3, 2026
Imagion Biosystems, Ltd. (ASX: IBX) has announced that the US Food and Drug Administration (FDA) completed its review of the company’s investigational new drug (IND)